Austin, Texas, United States, September 16th, 2026, NewsDirect
- VERAXA is developing antibody-based cancer therapies aimed at improving the therapeutic window of existing treatment modalities.
- Its proprietary BiTAC platform uses two complementary molecules that are designed to activate cytotoxic activity only when both recognize targets on the same tumor cell.
- The company is applying the BiTAC concept to both antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), with an emphasis on solid tumors.
- With ADCs and bispecific antibodies attracting substantial investment, VERAXA is operating in oncology markets where technological differentiation can have significant strategic value.
VERAXA Biotech (NASDAQ: VRXA) is developing a new generation of antibody-based cancer therapies at a time when oncology research is increasingly focused on a difficult question: how can powerful treatments be made more selective without sacrificing their ability to kill cancer cells? The wiss biotechnology company is approaching that problem through a portfolio of antibody-drug conjugates (“ADCs”), T-cell engagers (“TCEs”) and engineered antibody formats. At the center of the strategy is its proprietary BiTAC, or Bi-targeted Tumor-Associated Cytotoxicity, concept.
The objective is not simply to produce another antibody with a new target. VERAXA is attempting to change the…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Corporate Communications
IBN
Austin, Texas
512.354.7000 Office
Contact
IBN
www.InvestorBrandNetwork.com
[email protected]